Glycan Biosciences, a product-focused biotechnology company, has a proprietary carbohydrate-based chemistry platform to produce a novel class of new chemical entities (NCEs) called Glycanics™. Glycanics have anti-inflammatory activity which can be tailored to the various targets relevant for multiple indications. Glycan’s lead program is a compound being developed to treat severe, refractory asthma.